The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com



OncoMed Pharmaceuticals Inc. (OMED)

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. has four anti-cancer therapeutic candidates: Navicixizumab, which is a bispecific monoclonal antibody that targets and inhibits both Delta-like ligand 4, and vascular endothelial growth factor; Anti-TIGIT, which is an inhibitory receptor that stops T-cells from attacking certain tumor cells; GITRL-Fc, which is engineered using a single-gene, linkerless trimer technology that is designed to enable activation of glucocorticoid-induced tumor necrosis factor receptor-related protein; and Rosmantuzumab, which is a monoclonal antibody targeting the RSPO-LGR cancer stem cell pathway.

Company Name:  OncoMed Pharmaceuticals Inc.
Website:  www.oncomed.com
Sector:  Drugs & Pharmaceuticals
March 29, 2024    8:08 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree OMED Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

OncoMed Pharmaceuticals Inc. (OMED) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.